ArticleTranslational gastroenterology and hepatology2026
Efficiency of decentralized screening for hepatitis C in different healthcare settings: retrospective study over 6 years in southeastern Spain.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: One of the objectives proposed by the World Health Organization (WHO) for the period 2022-2030 is to employ new strategies to combat hepatitis. Since universal screening has not been implemented in Spain, opportunistic screenings are being conducted in different healthcare settings. This work analyses the efficiency of this process on the south-eastern region of Spain (Alicante). Methods: The efficiency of screening to detect hepatitis C virus (HCV) conducted in emergency, gynecology, surgery, primary care, nephrology, occupational risk accidents, and hematology (opportunist screenings) was compared against the screening conducted in prisons and in vulnerable populations (decentralized screening) using dry blood spot (DBS) testing between 2017 and 2023. The screening cost was calculated applying the Fee Law of the Valencian Community. Results: A total of 66,532 samples were analyzed, out of which viral genome was detected in 315 (0.47%). The prevalence of HCV-positive antibodies in patients from healthcare settings was 0.44%, of which 0.14% had detectable viral RNA (vRNA). In contrast, decentralised screening detected 27.28% positive HCV antibodies and 10.28% viral genomes. In this context, prisons showed a prevalence of positive antibodies and vRNA of 7.39% and 3.30%, respectively. In DBS samples, the prevalence of positive antibodies was 19.89%, with 6.98% showing vRNA. When analyzing the costs of screening processes, the costs of screening patients from gynecology are 89,966 € per patient positive for vRNA, decreasing to 6,744 € in primary care, to 2,983 € in the emergency department, to 518 € in prisons and to 405 € in DBS. Conclusions: Focusing on opportunistic screening, the most cost-effective approach is carried out in the emergency department. Regarding decentralized screening, this study has demonstrated that it is highly effective in our setting, as it targets disadvantaged populations with a high prevalence of infection. Therefore, this screening should be promoted and evaluated to establish its efficacy elsewhere and to advance the detection of patients infected with HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.